In vitro studies were performed to evaluate susceptibility tests with disks containing 10 p.g of ampicillin plus 10 ,ug of sulbactam. Interpretive zone standards of <11 mm (resistant), 12 to 13 mm (intermediate), and -14 mm (susceptible) are proposed. A nine-laboratory coordinated study was performed to establish tentative zone size limits for quality control of ampicillin-sulbactam disks. This included data with a new control strain selected to monitor performance of such combination disks.
Sulbactam (CP-45, 899) is a sulfone which irreversibly inhibits several important ,-lactamases (1, 2, 4) . By itself, sulbactam has little antibacterial activity against species other than Acinetobacter and Neisseria. However, when coadministered with a penicillin such as ampicillin, strains which are resistant to ampicillin by virtue of their ability to produce certain P-lactamases could be rendered susceptible to ampicillin (2, 9) .
For parenteral use, ampicillin and sulbactam are combined for coadministration. The pharmacokinetic properties of the two drugs are similar (3) . For purposes of in vitro susceptibility testing, ampicillin and sulbactam are normally tested in a fixed 1:1 ratio. For the disk diffusion test, disks containing 10 ,ug of ampicillin plus 10 p.g of sulbactam are to be recommended (data on file; Pfizer Central Research, Groton, Conn.).
The current study was designed to evaluate ampicillinsulbactam disks containing 10 ,ug of each drug in comparison with 10-»tg ampicillin disks. The results of such in vitro studies were analyzed to develop interpretive standards. In addition, the results of a nine-laboratory coordinated study are presented to establish tentative quality control parameters for ampicillin-sulbactam disks. This includes tests with a recently recommended control strain of Escherichia coli, selected to monitor disks which contain ,B-lactamase inhibitors combined with a 1-lactam (5 Disk diffusion tests were performed by the standardized procedure of the National Committee -for Clinical Laboratory Standards (7) . Disks containing 10 ptg of ampicillin plus 10 ,ug of sulbactam were provided by Pfizer Central Research, and 10-,ug ampicillin disks were prepared by BBL Microbiology Systems, Cockeysville, Md.
MIC interpretive breakpoints. Ampicillin MIC correlates for tests with enteric bacilli and enterococci are currently s8.0 ,ug/ml for the susceptible category and >16 ,ug/ml for the resistant category (7) . If either drug is to be used orally, another category of susceptibility would be appropriate, owing to the lower blood levels that might be anticipated, i.e., an MIC of '1.0 ,ug/ml for the susceptible category (8 We tentatively recommend the control limits defined in Table 1 for ampicillin-sulbactam disks. Both E. coli strains should be tested to monitor the two drugs in the combination disks. Ampicillin disks should be tested routinely against E. coli ATCC 35218, and, if zones are produced, one should suspect that the strain has lost its ability to produce ,-lactamase and a fresh culture should be obtained. If the sulbactam component of the combination disk loses potency, ATCC 35218 will produce smaller zones but ATCC 25922 zones will not be affected. The latter will be affected only by the ampicillin component in the disk.
Ampicillin versus ampicillin-sulbactam disks. Figure 1 presents data obtained with 396 gram-negative bacilli when zone diameters observed with ampicillin disks were compared with those observed with ampicillin-sulbactam disks. When sulbactam was added to the 10-,ug ampicillin disk, there was a significant increase in zone diameters with ampicillinresistant gram-negative bacilli, but the very susceptible strains gave equally large zones with both types of disks. Of the 396 gram-negative bacilli, 117 were resistant to ampicillin (zones, '11 mm) but susceptible to the ampicillin-sulbactam combination (zones, -14 mm). Six members of the family Proteeae were resistant to the combination but susceptible to ampicillin alone (possible antagonism). Acinetobacter spp. displayed rather marked differences in zone diameters with the two types of disks, possibly owing to the fact that some strains are quite susceptible to sulbactam alone. Our strains of Acinetobacter spp. provided MICs of 0.5 to 2.0 ,ug/ml with sulbactam alone and 0.25 to 2.0 ,ug/ml with the ampicillin-sulbactam combination. Additional analysis was carried out to establish the validity of the interpretive zone size breakpoints for different types of microorganisms.
Gram-negative bacilli and enterococci. Figure 2 presents the results of tests with ampicillin disks against 300 members of the family Enterobacteriaceae, 96 nonenteric bacilli, and 25 Streptococcus faecalis strains. Acinetobacter and Pseudomonas spp. were included despite the fact that there are currently no zone size standards for tests with nonenteric bacilli. For members of the family Enterobacteriaceae and enterococci, zone size breakpoints of '11 and .14 mm are currently recommended for tests with 10-,ug ampicillin disks. We observed 20 (4.7%) major or very major discrepancies among the 421 isolates. Ten With rare exception, P-lactamase-negative strains produced zones of -29 mm around ampicillin disks, and most ,Blactamase-positive strains produced zones of -20 mm. AIthough MICs with the latter were as low as 0.5 p.g/ml, they are considered to be resistant to ampicillin. Staphylococcal data with ampicillin-sulbactam disks are presented in Fig. 3 . With the exception of some methicillin-resistant strains (4 of 14 strains), sulbactam reduced all ampicillin MICs to .2.0 p.g/ml; MICs for all but one ,-lactamase-negative strain were s0.25 pg/ml. Early clinical experience in the treatment of penicillin-resistant staphylococcal infections with the ampicillin-sulbactam combination has been encouraging, thus suggesting that methicillin-susceptible, penicillinase-producing strains might be considered susceptible to the combination (A. K 14 strains were resistant to 2.0 ,ug/ml and 6 strains produced zones of <20 mm. All but one methicillin-resistant S. aureus strain produced ampicillin-sulbactam zones of .14 mm. Clinical experience with methicillin-resistant staphylococcal infections is currently inadequate to determine whether they are likely to be responsive to the ampicillin-sulbactam combination. Since we found no methicillin-susceptible staphylococci with zones of <20 mm, the susceptible category could be established at .20 or .14 mm with equal efficacy, providing that methicillin-resistant strains are assumed to be resistant, regardless of in vitro test results. The foregoing discussion is based on the conservative decision that methicillin-resistant staphylococci should be assumed to be resistant to the ampicillin-sulbactam combination regardless of the results of in vitro tests. This decision is tentative, because there are insufficient clinical data to determine the efficacy of ampicillin-sulbactam against this group of microorganisms. When such clinical data become available, interpretive standards for staphylococci should be reevaluated.
DISCUSSION
In summary, the interpretive criteria currently accepted for testing ampicillin disks against members of the family Enterobacteriaceae may be used for ampicillin-sulbactam disks (all species). The accuracy of ampicillin-sulbactam disk tests was found to be comparable or superior to that observed with ampicillin disks. Additional data have been presented to establish tentative zone size limits for quality control of ampicillin-sulbactam disks. This includes data with a new control strain which was selected for monitoring such combination disks.
LITERATURE CITED
